Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

In RCT (n=651) nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival in patients with previously untreated advanced renal-cell carcinoma (median 16.6 vs. 8.3 months, respectively, HR, 0.51; 95% CI, 0.41 to 0.64; p<0.001).

New England Journal of Medicine